Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaLaure Hirsch, Toni K. Choueiri, Ronan Flippot et al.|JAMA Oncology|2021Cited by 95
Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomesAndrew Leonard Laccetti, Matthew T. Campbell, Benjamin Garmezy et al.|Cancer Medicine|2021Cited by 19